ProfessorAlex Hewitt

Professor

Menzies Institute for Medical Research

  • Professor
    Menzies Institute for Medical Research
  • Menzies Institute for Medical Research, Menzies Institute for Medical Research, Hobart CBD Campuses, TAS

FUNDED PROJECTS

  • GRANT
    New Targeted Glaucoma Screening Program for High Risk Individuals
    3 Nov 2026 - 31 May 2029
    People funded by this grant:
    • Craig J,
    • Hewitt A,
    • Macgregor S,
    • Souzeau E,
    • Carnt N
    Project Total: $933,714; Glaucoma is the leading cause of irreversible blindness. Treatment is available to slow or stop glaucoma progression, but early diagnosis and interventions are critical to prevent blindness. Unfortunately, the lack of a cost- effective screening strategy has precluded a strategy to find individuals at-risk early. Moreover, half of affected individuals in the community are undiagnosed, and large-scale monitoring is required for all patients with suspicious signs, creating a major health burden. Family history is a major risk factor for glaucoma and 15-25% of unaffected individuals in the population have a family history of glaucoma. First-degree relatives of glaucoma patients have a risk of developing the condition up to nine times higher than the general population. However, varying genetic risk levels exist amongst family members. Our industry partner Seonix Bio has successfully developed a NATA-accredited clinical polygenic risk test (PRS) for glaucoma which can effectively determine an individuals genetic risk, and stratify risk within an enriched risk population such as those with a family history. This project will translate an innovative targeted screening program, applying PRS to identify those at high risk among individuals with a family history, and implement a digital recall system to alert individuals for ongoing monitoring. We will generate the evidence base required to support translation of the targeted program into practice and policy. We will address known barriers to implementation, facilitating nationwide cross-sector knowledge transfer through the development of educational resources for healthcare professionals and patients with the support of Glaucoma Australia, and clinical recommendations and guidelines for successful PRS implementation. Collectively, these will contribute to Glaucoma Australias national action plan to enable early detection and prevent irreversible blindness. Funded by: National Health & Medical Research CouncilNational Health & Medical Research Council - Grant-Partnership Project; University of Tasmania.
  • GRANT
    Determining the gene correction threshold required to cure CLN2 disease
    1 Jun 2026 - 1 Jun 2027
    People funded by this grant:
    • Hewitt A,
    • KC R
    Project Total: $70,000; This proposed research will directly compare gene-based editing therapies for Battens disease. We will be applying the leading gene editing technology for CLN2. The in vivo delivery of highly efficient gene editors will confirm whether disease progression be halted. In our preliminary studies, co-transduction of intein-split ABE8e halves achieved robust editing in vitro; however, in vivo delivery (intracranial injection at postnatal day 1) of these constructs were not sufficient to treat CLN2 mice. Our proposed research seeks to overcome the limitations of current in vivo base editing approaches through the development of a stitchR-based split ABE8e and integrase system, in which reconstitution occurs at the mRNA level rather than at the protein level. By bypassing the inefficiencies of intein-mediated protein splicing, stitchR-split ABE8e when delivered as a one-time dual AAV treatment is expected to increase the availability of full-length ABE8e in neurons and thereby enhance the edit rate required for therapeutic benefit. We will also apply the stitchR technology to integrases. In time, this work will also provide insight into which gene-based therapies have the potential for the fastest translation from bench to bedside, and should be prioritised for clinical development. Funded by: Batten Disease Global Research Initiative - Batten Disease Global Research Initiative Grant Program; Jack's Thousand Days Foundation ($69,907); University of Tasmania.
  • CONSULTANCY/CONTRACT RESEARCH
    CellTellus Code
    22 Mar 2026 - 30 Jun 2026
    People funded by this grant:
    • Hewitt A
    Project Total: $55,000; CellTellus is aiming to commission contract work to generate a standard code for computational analysis. CellTellus is a biotechnology company pioneering a new approach to therapeutic discovery through induced pluripotent stem cell (iPSC) technology. By integrating advanced stem cell science with cutting-edge genomics and analytics, we model human disease at unprecedented scale and resolution. This enables the discovery and validation of novel drug targets, reduces risk in clinical programs, ultimately enabling faster, more effective treatments for patients worldwide. Funded by: CellTellus Pty Ltd ($54,936); University of Tasmania.
  • GRANT
    Developing stem cell villages in a dish to develop new therapeutics for retinal diseases
    18 Feb 2026 - 18 Feb 2027
    People funded by this grant:
    • Pebay A,
    • Powell J,
    • Hewitt A
    Project Total: $498,108; We use patient stem cell-derived models to discover novel therapeutics for neurodegenerative diseases, in particular blinding diseases. Our ultimate vision is to engineer new therapies for conditions that urgently need effective treatments. Translating this work into commercial outcomes involves innovative manufacturing of biological materials ('disease in a dish') and advanced analytics (machine-learning methods for genomic analysis). Here, we will optimise methods to grow 'retinal villages', comprising mutliple patients' lines and machine-learning methods to identify patterns in patients presentations of ophthalmic diseases, to allow for more precise and personalised approaches to patients' treatments. Our project aims to produce a 'retinal village in a dish, an advanced in vitro model composed of retinal cells from multiple patients in a single dish, using human induced pluripotent stem cells (iPSCs). The village provides a powerful tool for studying retinal diseases, identifying therapeutic targets, and testing potential treatments in a human-relevant and tissue-specific context. The market for such cutting-edge in vitro models is growing, especially in drug discovery and development, given the pressing need for more accurate models to emerge. Our advantage lies in the precision and scalability of our iPSC-derived retinal village, which offers a more comprehensive and physiologically relevant model than current alternatives. To date, we have successfully established the foundational components of our approach, including the generation of patients own iPSC lines (over 600 lines), and differentiation of cells into retinal pigment epithelium (RPE) cells, which are the cells involved in age-related macular degeneration and various inherited retinal diseases. We have also established key parameters for iPSC villages, in particular for their differentiation towards cardiac and brain lineages, but not yet retinal cells. Moving towards commercialisation requires the full set-up and optimisation of the retinal village. Funding is needed now to accelerate the Technology Readiness Level (TRL) of our village in a dish approach, enabling us to optimise the system to ophthalmic applications, conduct essential validation studies, and bring this innovative model to market, where it can significantly impact the development of new and personalised treatments for retinal diseases. Funded by: Department of Education - Grant - AEA Ignite; University of Melbourne; University of Tasmania.
  • GRANT
    Genetically guided therapy choice for gastrointestinal autoimmune disorders - The Leveraging pharmacogenomics to Optimise Choice of IBD therapy (LOCI) validation trial
    1 Aug 2024 - 1 Aug 2026
    People funded by this grant:
    • Powell J,
    • Hold G,
    • El-Omar E,
    • Leong R,
    • James K
    Project Total: $2,762,256; Inflammatory bowel disease (IBD) is a condition in which there is chronic or recurring inflammation of the gastrointestinal (GI) tract, for which there is currently no cure; with Australia having one of the highest incidence rates globally. We live in the golden age for targeted treatment of IBD, with biologic monoclonal antibody agents such as anti-TNF antibodies, anti-integrins and anti-IL 12/23 antibodies, and JAK inhibitors, as major classes of treatment for the management of symptoms. Despite increasing treatment options, contraindications, primary non-response, secondary loss of response, and intolerance often occur. Approximately 30% of patients do not respond to biologics, and 1020% per year lose response after initial improvement, requiring dose escalation or a switch to another drug class. Currently, we cannot predict which patients will respond to a particular therapy, limiting our ability to personalise treatment. We are seeking funding to develop a novel, highly innovative diagnostic device to predict patient response to IBD biological therapies enabling precision treatment choices via a simple pharmacogenomic test. We will do so by utilising population-level cellular data from our world-leading Onek1k cohort, which has revealed how genetics influence the expression of drug targets at the level of individual immune cells. Coupled with machine learning and validation at the proteomic level from patient gut biopsies, we will create a library of predictive outcomes for an individuals genome and perform validation trials. Funded by: Medical Research Future Fund - Grant - Genomics Health Futures Mission; University of Tasmania.
  • GRANT
    POPSTEM: Patient-specific cardiac stem cell villages for personalised therapeutic design
    1 Jun 2024 - 31 May 2029
    People funded by this grant:
    • Powell J,
    • Figtree G,
    • Neavin D,
    • Vandenberg J,
    • Hill A
    Project Total: $4,999,499; Cardiovascular Diseases (CVDs) are the leading cause of death both nationally and globally, responsible for 26% of all deaths in Australia and costing the Australian economy more than $5bn each year. Although advances in diagnosis and treatment options have reduced total mortality in the past decades, over 20% of patients who suffer an acute myocardial infarction (MI) will die in the year following, and over half of those in the 30 days following The Problem We know that patients that suffer ventricular arrhythmias post-MI have an increased risk of sudden cardiac death and higher overall mortality However, whilst work has identified lifestyle and genetic factors associated with higher risk of ventricular arrhythmias post-myocardial infarction, these factors explain only 20% of this risk Predicting which patients will suffer from ventricular arrhythmias and then which of those will suffer sudden cardiac death post-MI is currently not possible The Solution Using our cutting-edge stem cell village models and our world-leading BioHEART-CT cohort, we will assess the cellular and molecular factors that lead to cardiovascular disease and sudden cadiac death post-MI. We will build a drug screening platform to inform therapy choice and de-risk insudtrys drug development pathways. Funded by: Medical Research Future Fund - Stem Cell Therapies Mission; Garvan Institute of Medical Research; Macquarie University; University of Melbourne; University of New South Wales; University of Queensland; University of Sydney; Victor Chang Cardiac Research Institute Limited; University of Tasmania.
  • GRANT
    Applying OCCAMS molecular razor to study the role of EBV in MS pathogenesis
    1 Jan 2024 - 31 Dec 2028
    People funded by this grant:
    • Phan T,
    • Massey J,
    • Hewitt A,
    • Yazar S,
    • Goodnow C
    Project Total: $2,000,000; Strong epidemiological and clinical evidence suggests that infection with the Epstein-Barr Virus (EBV) is necessary but not sufficient to cause multiple sclerosis (MS). In Australia, EBV infects >90% of the healthy adult population, yet only 1 in 1000 develop MS. This suggests that variability in an individuals immune response to EBV may contribute to MS pathogenesis. Familial and genome-wide association studies (GWAS) have identified several immune response genes, including HLA-DR15, as risk factors. However, their precise contribution to the variability in the immune response to EBV and how this leads to MS is unknown. To resolve this, we have assembled a world- class interdisciplinary team of clinicians, scientists and consumers working in hospitals, research institutes, universities and consumer organisations from Australia and around the world to form the Open Coast-to-Coast Australian Multiple Sclerosis (OCCAMS) consortium. OCCAMS include internationally recognised thought leaders in virology (EBV), neurology (MS), immunology (B cells, T cells, and autoimmunity), and consumer engagement. We have invented and pioneered new technologies such as single cell expression quantitative trait loci (eQTL) mapping, single cell multiomics and simultaneous immune repertoire and transcriptome sequencing. OCCAMS, in collaboration with our industry partners, will leverage these state-of-the-art technologies to interrogate established cohorts of patients with severe MS who have undergone autologous haemopoietic stem cell transplantation (AHSCT), and new cohorts of first demyelinating episodes, and first-degree relatives to determine the differences in the immune response to EBV of individuals who are EBV-positive with MS, EBV-positive without MS, and EBV- negative without MS. We will use machine learning to build a model that explains the variability and generate biomarkers that can predict an individuals risk and form the basis for future primary prevention studies. Funded by: Medical Research Future Fund - Grant - Emerging Priorities and Consumer Driven; University of New South Wales; University of Tasmania.
  • GRANT
    Variant Evaluation and Refinement for Integration of Functional Insights for ABCA4
    1 Jul 2023 - 31 Oct 2024
    People funded by this grant:
    • Hewitt A,
    • KC R
    Project Total: $190,700; The ABCA4 (ATP-binding cassette transporter A4) protein is essential in the visual cycle and acts as an Adenosine triphosphate (ATP)-binding cassette transporter in photoreceptor outer segments. ABCA4 imports N-retinylidene-phosphatidylethanolamine into photoreceptors, and dysfunction results in cytotoxic accumulation of lipofuscin in the retinal pigmented epithelium (RPE). ABCA4 is solely expressed in photoreceptor and RPE cells. Disease-causing missense, nonsense, canonical splice and deep intronic variants in ABCA4 have been shown to cause dysregulation of ATPase activity. Given the number of emerging gene-based therapies for Stargardt disease and ABCA4-related cone-rod dystrophy we have designed a series of assays to facilitate the characterisation of all possible disease-causing variants. VUS will initially be evaluated for their putative mechanism and the appropriate assay will be applied for function interrogation. Assays have been specifically selected based on the timeliest turn-around for detection-to-functional insight as well as their clinical robustness. Funded by: Australian Functional Genomics Network - Grant ($190,700); University of Tasmania.
  • GRANT
    Implementing a novel model of management for glaucoma using polygenic risk profiling
    1 Jun 2023 - 31 May 2027
    People funded by this grant:
    • Craig J,
    • Hewitt A,
    • Siggs O,
    • Souzeau E,
    • Kitson A
    Project Total: $2,934,013; Glaucoma is the leading cause of preventable irreversible blindness worldwide. Loss of driving licence, and independence with legal blindness are common in late stage disease. There is strong evidence that lowering intraocular pressure delays disease progression, but imprecise risk assessment results in both under and overtreatment creating a substantial burden on health services. Glaucoma is highly heritable, and an exemplar of early molecular diagnosis and profiling enabling anticipatory care and the prevention of blindness. This project will implement our novel glaucoma polygenic risk score (PRS) to enable specialist care to be prioritised for those patients at highest risk of vision loss, reducing the health economic impact of blindness and increasing efficiency in our health system with a protocolised model of care. This is a scalable approach, ready to be adopted in both community and specialist care settings. This study will provide a framework by which a NATA accredited PRS for glaucoma can be ordered by clinicians and the results seamlessly incorporated into a collaborative-care pathway. Our novel PRS-guided system of care will enable early glaucoma cases to be assessed in conjunction with clinical risk factors. This system will identify individuals most at risk of vision loss needing urgent specialist care, so unnecessary delays in treatment can be avoided which will prevent later blindness. It directly addresses the lack of precise tools to characterise patients risk level, and delays in specialist referral and management due to limited health system capacity. The project is built on a foundation of longitudinal data from the worlds largest study of early glaucoma, which will be used to develop a triage and monitoring system integrating both clinical and PRS data to provide decision support. This is a paradigm shift in glaucoma management, and will improve access to care for all patients enabling early treatment for high risk patients. Funded by: Medical Research Future Fund - Grant - Genomics Health Futures Mission; Flinders University; University of New South Wales; University of Western Australia; University of Sydney; Queensland Institute of Medical Research; University of Adelaide; Macquarie University; Adelaide University; University of Tasmania.
  • GRANT
    PAGETURNA: Pioneering Application of Gene Editing to Transplant Using RNA
    1 Apr 2023 - 31 Mar 2026
    People funded by this grant:
    • Deans A,
    • Hewitt A,
    • Fairfax K
    Project Total: $979,980; The aim of PAGETURNA is to develop cutting-edge gene editing technologies that prevent children and young adults from dying of inherited bone marrow failure syndromes (BMFS). PAGETURNA will improve stem cell transplant success rates, reduce costs, side effects and stress on families, and enable rapid translation into practice. Funded by: Medical Research Future Fund - Grant - Stem Cell Therapies Mission; St Vincent's Institute of Medical Research; University of Tasmania.
  • GRANT
    A new substrate reduction strategy to treat childhood dementias: Glucosylceramide synthase-targeting antisense oligonucleotides
    1 Jan 2023 - 31 Dec 2025
    People funded by this grant:
    • Cook T,
    • Aung-Htut M,
    • Perry S,
    • King A,
    • Wilton S
    Project Total: $599,978; Lysosomal storage disorders (LSDs) contribute to the burden of childhood dementia and are characterised by accumulation (storage) of macromolecules, due to loss-of-function mutation of lysosomal enzymes. One treatment strategy for LSDs is substrate reduction therapy, which aims to limit the production of macromolecules to a level at which residual enzyme activity is sufficient to prevent accumulation. Glucosylceramide synthase (GCS) is a widely expressed enzyme that catalyses the first step in synthesis of glycosphingolipids, a lipid that accumulates in many LSDs. Inhibition of GCS using miglustat (Zavesca) is currently approved in some countries to treat several LSDs, however, gastrointestinal side effects, weight loss, and tremor are common, and it has a low ability to transverse the blood-brain barrier limiting its' use for childhood dementia. Here we will develop an approach complementary to pharmacological inhibition of the GCS enzyme, by developing antisense oligonucleotides (ASOs) and testing their ability to decrease expression of GCS and thereby lower glycosphingolipid accumulation. ASOs are an ideal complementary therapy to agents such as miglustat because they target the GCS-encoding mRNA to decrease the amount of enzyme produced, and can exert long-lasting effects throughout the brain when delivered to pre-clinical animal models or humans. We have hypothesised that GCS-trageting ASOs will provide benefit to multiple LSDs that cause childhood dementia, because of close genetic and biochemical association with gylcosphingolipid metabolism or through pre-clinical studies where miglustat and related small molecular inhibitors of GCS have rescued disease-related phenotypes. We will use multiple human cell-based models to determine diseases where GCS-targeting ASOs are effective, and test target engagement in mice. We anticipate GCS-targeting ASOs will bridge the gap to disease-modifying therapies for LSDs and improve care for children with dementia. Funded by: Medical Research Future Fund - Grant - Preventative and Public Health Research ($599,978); University of Tasmania.
  • GRANT
    A randomised controlled trial in genetically at-risk individuals to determine the efficacy of early laser treatment in preventing glaucomatous vision loss.
    1 Jan 2023 - 31 Dec 2026
    People funded by this grant:
    • Craig J,
    • Hewitt A,
    • Graham S,
    • Casson R,
    • Souzeau E
    Project Total: $1,734,318; Primary open angle glaucoma (POAG) is the commonest cause of irreversible vision loss. In the early stages of POAG before visual field loss has occurred, definitive diagnosis can be difficult. This has led to a large number of referrals (glaucoma suspects) requiring regular monitoring. There is a major gap in knowledge relating to how to identify individuals destined to become blind from glaucoma, and how they may be safely treated earlier in the course of disease. Once vision loss has been observed, selective laser trabeculoplasty (SLT) has been shown to be a safe and effective primary intervention for POAG. We recently developed a glaucoma polygenic risk score (PRS), which effectively stratifies risk in glaucoma suspects and patients with early disease for development and progression of disease respectively, as well as treatment intensity. Prospective evaluation of Australian glaucoma suspects by our group over the past 8 years has determined that our glaucoma PRS, combined with clinical risk factors, is highly predictive of future vision loss. In addition, the burden of glaucoma suspects requiring regular monitoring according to current guidelines is unsustainable, so new monitoring and treatment strategies are required. In this trial, 500 high-risk glaucoma suspects will be enrolled after completing comprehensive risk stratification, with at least 400 randomised to receive either SLT or sham SLT. All participants will be followed 6-monthly for two years, with a primary endpoint of conversion to glaucomatous visual field loss or unacceptably elevated intraocular pressure, either of which would necessitate intervention as part of standard clinical care. The insights gained from this trial will have immediate translational implications for policy development and the rational deployment of an evidence-based glaucoma suspect monitoring and treatment program both in Australia and Internationally. Healthcare savings will accrue by prevention of glaucoma related morbidity. Funded by: National Health & Medical Research CouncilNational Health & Medical Research Council - Grant-Clinical Trial and Cohort Studies; Flinders University; University of Tasmania.
  • GRANT
    Engineering Novel Gene Therapy and Delivery System for Correcting Inherited Retinal Diseases/Developing Therapeutic Engineered Virus-Like Particles to Target Genetic Diseases of the Retina
    1 Jan 2023 - 31 Dec 2025
    People funded by this grant:
    • Lisowski L,
    • KC R,
    • Hung S,
    • Hewitt A
    Project Total: $743,677; Many blinding eye diseases manifest by the degeneration of retinal cells and collectively inherited retinal diseases (IRD) are now the leading cause of blindness in working-aged adults. Despite the identification of specific mutations causing many inherited retinal dystrophies, most of these conditions are still currently untreatable. Recent advances in genetic engineering have led to the development of treatments for many genetic disorders, including using viral vectors for delivering gene editing machinery. Even with these exciting advances in gene therapy, challenges remain for treating the vastly diverse genetic mutations of inherited retinal diseases. The aim of our research is to integrate and enhance custom gene-editing technology with novel viral delivery systems to create a personalised treatment for the patient's specific disease-causing mutation. The project will develop a method for directed evolution of lentiviral vectors to target specific cell types of the retina. The evolved lentivirus glycoprotein with improved transduction in specific retinal cells will be used to generate engineered virus like particles (eVLPs) for effective delivery of gene editing tools as ribonucleoprotein into the retinal cells. Thus, developed retinal cells-targeting eVLPs will be used to deliver prime editors to correct disease-causing mutations in retinal cells both in vitro and in vivo using cell and mouse models of inherited retinal diseases, respectively. This delivery tool will have a wider application in clinical translation in vivo genome editing for developing therapies for but not limited to inherited retinal diseases. Funded by: National Health & Medical Research CouncilNational Health & Medical Research Council - Grant-Ideas; University of Sydney; University of Tasmania.
  • GRANT
    Harnessing genetics to halt the sneak thief of sight.
    1 Jan 2022 - 31 Dec 2026
    People funded by this grant:
    • Hewitt A
    Project Total: $2,072,570; Glaucoma is the leading cause of irreversible blindness worldwide. Open-angle glaucoma is often referred to as the sneak thief of sight? as the early stages are asymptomatic, but the natural history is progressive loss of peripheral vision, at rates that differ markedly between individuals and, in advanced cases, lead to total blindness. Loss of driving licence is a common outcome in intermediate stage disease, with legal blindness and complete loss of independence in late stage disease. Glaucoma is one of the most heritable diseases and one of the few conditions where early molecular diagnosis and profiling will enable anticipatory care and the prevention of blindness. Over the next five years, my collaborative team will build an evidence-base for glaucoma screening, which incorporates genetic testing - a first for glaucoma management and risk stratification. Research Program 1 will ensure that Australia continues to lead the world in glaucoma genetic discovery, and within five years we will implement evidence-based, genetic risk profiling to reduce the blindness burden for open-angle glaucoma. Genome-wide association study design has proven to be a robust means to dissect complex traits, and next-generation sequencing approaches are rapidly yielding highly penetrant causative variants. To date, much of our effort on clinical translation has focussed on monogenic forms of glaucoma; however, through recent discoveries we are now ready to robustly assess the clinical implementation of polygenic risk profiling for this blinding disease. In Program 2 & 3, my team will harness induced pluripotent stem cell, genome-wide association study design, and CRISPR/Cas technology, to open the transformative power of expression quantitative trait mapping and transcriptional profiling at a single cell resolution, in cells directly involved in glaucoma disease pathogenesis. This work will enable the immediate prioritisation of novel therapeutic targets for glaucoma. Funded by: National Health & Medical Research CouncilNational Health & Medical Research Council - Fellowship-Investigator Grant ($4,145,140); University of Tasmania.
  • GRANT
    Isogenic iPSC models with CLN3 variants for high throughput drug screening
    11 Mar 2021 - 15 Feb 2022
    People funded by this grant:
    • Cook T,
    • Hewitt A,
    • King A,
    • Perry S
    Project Total: $49,400; To advance therapeutic strategies for Batten disease, we will use our existing isogenic iPSC models with CLN3 variants to: Aim 1: Measure CLN3-dependent changes in neuronal network activity using multielectrode arrays. Aim 2: Quantify CLN3-dependent changes in lysosomal, mitochondrial and autophagy function in neurons. Aim 3: Identify CNS-penetrant drugs that exhibit efficacy against CLN3-variant associated neuron changes. Funded by: Batten Disease Support and Research Association - Grant-Research ($49,400); University of Tasmania.
  • CONSULTANCY/CONTRACT RESEARCH
    Development and validation of a gene editing therapy for CLN2-related disease
    1 Jan 2021 - 15 Feb 2022
    People funded by this grant:
    • Hewitt A
    Project Total: $50,000; We have recently compared the base editing profile of circularly permuted and domain inlaid base editors, characterizing their transcriptomic signature at promiscuous RNA transcripts, and have found that the RNA off-target profile of base editors can be modulated by their secondary structural arrangement. With this insight, we engineered the first high-efficiency, high-fidelity, miniaturized adenine base editor (ABE) that can comfortably fit within the packaging constraints of adeno-associated virus (AAV)-delivery systems. Our variant of the ABE (microABE-I744?) has up to a 22-fold improvement to on-target DNA editing compared to Staphylococcus aureus (Sa) Cas9 variants with N-terminal linked ABEmax and the recently described, miniABEmax. Additionally, the microABE-I744 has a dramatically reduced RNA-off target footprint on the transcriptome compared to existing SaCas9 ABE variants without sacrificing robust on-target editing, and can also be successfully packaged into AAVs. Building on this pilot data, we now aim to directly correct a disease-causing variant in a pre-clinical model of CLN2. Funded by: Batten Disease Support and Research Association ($50,000); University of Tasmania.
  • GRANT
    Strong, fast, then none: development of novel promoters for gene-editing therapies
    1 Jan 2021 - 31 Dec 2021
    People funded by this grant:
    • Hewitt A
    Project Total: $38,000; This work expands on our development of novel domain inlaid base editors which can facilitate the direct correction of a well-established disease-causing variants for a vast array of inherited retinal diseases. The overriding hypothesis of this research is that novel promoter sequences can be developed, and throughput profiling will facilitate the timely and safe application of this leading gene-editing technology. The specific aims of this work are to: 1) Synthesize, clone and screen amenable disease-causing variants annotated in the ClinVar database for their suitability of correction using our novel micro-ABE. 2) Develop and profile novel synthetic promoters, which are readily silenced following initial expression. Funded by: Retina Australia - Grant-Research ($38,000); University of Tasmania.
  • GRANT
    Translating patient stem cells into personalised screens for age-related macular degeneration
    1 Sep 2020 - 31 Aug 2022
    People funded by this grant:
    • Pebay A,
    • Hewitt A
    Project Total: $881,907; There are no treatments to prevent or reverse vision loss from the dry form of age-related macular degeneration (AMD). This is largely due to the fact that there are currently no good models in which to study AMD, haltering the discovery of efficient treatments. Patient induced pluripotent stem cells (iPSCs), are a powerful tool to investigate retinal disease, as cells from selected individuals or specific genetic background can be differentiated into specific cell types to make a biopsy in a dish? and obtain disease models for therapy development. It is well established that the retinal pigment epithelium (RPE) is compromised, and integral to the disease process in AMD. Using iPSCs, we and others demonstrated that RPE cells produce drusen-like deposits - key pathological markers of AMD- that are detectable using simple microscopy techniques. This discovery brings to the forefront of research a novel, powerful and pathologically relevant model of human retinal disease. We will extend on this recent finding by using high throughput screening platforms coupled with cutting edge microscopic techniques to detect drusen in patient iPSC-derived RPE cells; use this methodology for screens of therapeutical candidates, select hits and screen for impact on drusen in patient lines for subsequent clinical translation. Findings from this critical proof of concept in vitro research will bridge the gap in current models, with the intention of identifying appropriate drug candidates for clinical therapy of rAMD It will thus allow the screening and identification of novel therapeutical approaches to treatments of AMD using patient cells. Funded by: Medical Research Future Fund - Grant - Stem Cell Therapies Mission; University of Tasmania.
  • GRANT
    Bone marrow failure syndromes
    16 Jun 2020 - 10 Dec 2023
    People funded by this grant:
    • Hewitt A
    Project Total: $49,161; This project will be fundamental for the functional validation of the putative loci effecting blood cell phenotypes identified through the GWAS-based mapping of bone marrow expression profiles. The project would involve collecting primary samples, performing CRISPR modification of cell lines and primary human hematopoeitic stem cells. In addition some basic analysis in R and work with scRNAseq datasets will be performed. Funded by: Maddie Riewoldt's Vision - Scholarship - Alex Gadomski PhD ($49,161); University of Tasmania ($49,161).
  • GRANT
    Gaining new insights into metastatic bone tumours
    1 Jan 2020 - 30 Jun 2021
    People funded by this grant:
    • Dickinson J,
    • Holloway A,
    • Nott L,
    • Liu G-S,
    • FitzGerald L
    Project Total: $24,925; Molecular analysis of prostate cancer tumour specimen to identify new molecular targets for therapy. Funded by: Royal Hobart Hospital Research Foundation - Grant-Project ($24,925); University of Tasmania.
  • GRANT
    Functional interrogation of loci associated with the regulation of haematopoiesis
    1 Mar 2019 - 30 Jun 2021
    People funded by this grant:
    • Fairfax K,
    • Hewitt A
    Project Total: $149,512; New therapies and markers for bone marrow failure will be identified by answering fundamental questions such as What genes determine the proportion of specific cell types in the blood?? and What are the underlying genetic drivers for gene expression in different blood cells?? This work will harness the power of genome-wide association analysis, where all common genetic variants are compared between people, and single cell RNA-seq, a disruptive and ground-breaking technology that enables the direct quantification of gene expression in individual cells. This research will build upon work underway, which aims to identify cell and context-specific mutations that vary in their functional effect on blood cell phenotypes. We are currently aiming to catalogue, at scale, the genetic drivers of specific sub-populations of blood cells. Using seed MRV funding we are collecting and processing bone marrow aspirate samples from healthy people in Tasmania. To expand this work, the Maddie's Vision / Alex Gadomski Fellow will undertake functional experiments to molecularly characterize the identified loci. Funded by: Maddie Riewoldt's Vision - Fellowship - Alex Gadomski ($149,512); University of Tasmania.
  • GRANT
    Pre-clinical validation, optimisation, and safety profiling of CRISPR/Cas-base editing for PCDH15-related disease.
    1 Feb 2019 - 30 Jun 2020
    People funded by this grant:
    • Hewitt A,
    • Pebay A,
    • Cook T
    Project Total: $733,314; The overriding hypothesis of this work is that Clustered Regularly Interspersed Short Palindromic Repeat (CRISPR) and CRISPR-associated (Cas) technology can be used as an anticipatory cure to well-defined inherited retinal diseases caused by single nucleotide substitutions. The aim of this proposal is to use patient-specific induced pluripotent stem cells (iPSCs) to demonstrate the safety and efficacy of CRISPR/Cas-base editing constructs for the anticipatory cure of Usher Syndrome. In preparation for a Phase 1, first in human clinical trial, we will construct and test single vector plasmids to deliver SaCas9 with an appropriate promoter, single guided RNA (sgRNA) and an optimised adenine base editor (ABE) to correct the Arg245Ter PCDH15 disease causing variant. Funded by: Medical Research Future Fund - Grant - Accelerated Research ($733,314); University of Tasmania.
  • UTAS INTERNAL FUNDING
    High-Content and High-Throughput Platforms for Analysis of Stem Cells and their Derivatives
    1 Jan 2019 - 31 Dec 2019
    People funded by this grant:
    • Hewitt A,
    • Cook T,
    • Dickson T
    Project Total: $1,700,000; This proposal is for strategic and specialised equipment underpinned by basic infrastructure required to support neurodegenerative disease research within the CHM. Funded by: University of Tasmania; University of Tasmania.
  • GRANT
    Proteomic analysis of exosomes from iPS cell-derived neurons with mislocalised TDP-43
    1 Jan 2019 - 1 Jan 2020
    People funded by this grant:
    • Cook T,
    • King A,
    • Atkinson R,
    • Perry S,
    • Hewitt A
    Project Total: $99,665; Our overarching hypothesis is that TDP-43 mislocalisation leads to altered axonal and exosomal protein expression, and which may underpin the mechanism of TDP-43 pathological spread leading to neurodegeneration of motor circuits in ALS. To begin testing this hypothesis, we have designed experiments to address three Specific Aims: Aim 1: To characterize human iPS cell-based models of TDP-43 mislocalisation Aim 2: To quantify proteins differentially expressed in axons and exosomes of iPS cell-derived neurons with and without TDP-43 mislocalisation Aim 3: To quantify transmission of TDP-43 mislocalisation and altered phosphorylation in a human cerebral organoid model Funded by: Motor Neurone Disease Research Australia - Grant - Innovator ($99,665); University of Tasmania.
  • GRANT
    Rapid antibody development for improved cancer immunotherapy diagnostics
    1 Jan 2019 - 17 Nov 2020
    People funded by this grant:
    • Flies A,
    • Hewitt A,
    • Nott L
    Project Total: $9,841; Development of tools such as monoclonal antibodies to study the immune system can be time consuming, costly, and technically challenging. Recently, a technique called phage-assisted continuous evolution (PACE) was developed to harness the rapid evolution of bacteriophages to produce novel biomolecules1,2. We have recently established the PACE system here at Menzies, and we will now apply this system to the development of monoclonal antibodies. We will use the PACE system to produce single-domain antibodies (sdAb, aka Nanobodies). sdAbs are derived from the variable coding region of heavy-chain only antibodies from the camelid family (e.g. camels, llamas, alpaca). The unique heavy chain only antibodies from camels are simpler to produce than antibodies from other species because they require only one protein-coding gene sequence (e.g. the variable region), whereas other species require at least a heavy chain variable region, a light chain variable region, and in most cases the heavy and light chain constant regions. sdAbs have been shown to a protein binding capacity similar to traditional antibodies, but have the added benefit of being very small, which facilitates their use in applications that require small proteins. Importantly, the ability of a single gene to produce a high-affinity antibody lends itself to the PACE system because only one gene needs to be evolved, thus eliminating complications of matching heavy and light chain genes to produce a functional antibody. We will initially reproduce a published sdAb that targets a key immune molecule3 to demonstrate our capacity to make sdAbs. Then we will produce a phage library that represents the germline heavy chain only variable regions encoded in the camels, llamas, and alpaca genome. We can then allow the phages to compete for binding to target antigens and allow evolution to produce a high-affinity sdAb in a few weeks. Traditional monoclonal antibodies take 2-6 months to produce. Funded by: Royal Hobart Hospital Research Foundation - Grant-Incubator ($9,841); University of Tasmania.